Back to Search
Start Over
Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.
- Source :
- Pediatric Transplantation; May2017, Vol. 21 Issue 3, pn/a-N.PAG, 9p
- Publication Year :
- 2017
-
Abstract
- We conducted a retrospective analysis of outcomes for children and young adults with sAML/ sMDS who underwent HSCT at our institution. Thirty-two patients (median age 20 years) with sAML (n=24) and sMDS (n=8) received HSCT between 1990 and 2013. The median time from sAML/ sMDS diagnosis to HSCT was 4.1 months (range: 1.2-27.2 months). The transplant regimens were primarily busulfan based (n=19). BM was the primary donor source (n=15). Eleven recipients were transplanted with residual disease. At a median follow-up of 62.3 months (range: 0.4-250.9 months), 14 patients had disease recurrence. Acute GVHD, grade III/ IV, occurred in three patients. Causes of death were as follows: disease relapse (n=12), infection (n=2), pneumonia (n=1), pulmonary hemorrhage (n=1), acute GVHD (n=1), and graft failure (n=1). A PS of ≥90% at the time of HSCT had a significant impact on PFS ( P=.02). Patients achieving pretransplant primary CR (n=8) and those with sMDS and RA (n=6) had prolonged PFS ( P=.04). On multivariate analysis, shorter time to transplantation (≤6 months from diagnosis of sAML/ sMDS) was associated with superior OS ( P=.0018) and PFS ( P=.0005). [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13973142
- Volume :
- 21
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Pediatric Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 122274055
- Full Text :
- https://doi.org/10.1111/petr.12890